1AI 0.00% 0.7¢ algorae pharmaceuticals limited

Passing Through the 20's, page-125

  1. 20 Posts.
    lightbulb Created with Sketch. 2
    Question. Isn't phase 2 study still primarily a safety study.
    Actual improvement which is sustained has very interesting implications. Suggests the treatment is more than just neuroprotective. Astonishing if true. I wonder if they have had the chance to examine the brain of one of the early subjects yet?
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.